Recombinant Human Tumor Necrosis Factor-alpha Variant
This product is for research use only. It is not approved for use in humans, animals, or in vitro diagnostic procedures.
The clinical use of the potent antitumor activity of TNF-α has been limited by the proinflammatory side effects including fever, dose-limiting hypotension, hepatotoxicity, intravascular thrombosis, and hemorrhage. Designing clinically applicable TNF-α mutants with low systemic toxicity has been an intense pharmacological interest. Human TNF-α, which binds to the murine TNF-α55 but not to the murine TNF-α75, exhibits retained antitumor activity and reduced systemic toxicity in mice compared with murine TNF-α, which binds to both murine TNF receptors. Based on these results, many TNF-α mutants that selectively bind to TNF-α55 have been designed. These mutants displayed cytotoxic activities on tumor cell lines in vitro, and exhibited lower systemic toxicity in vivo.
| 目录编号 | 103-01V |
|---|---|
| 制造国家 | 美国 |
| 产品编码 | rhTNF-α variant |
| 规格/数量 | 10ug, 50ug, or 1mg |
| 产品用途 | 本产品仅供研究使用。未经批准，不得用于人体、动物或体外诊断程序。 |
| 储存 | 收到后，请储存于 -20°C。复溶后，可在 2-8°C 保存最多一周。为获得最大稳定性，请分装并储存于 -20°C。避免反复冻融。 |
| 运输 | 干冰。 |
| Synonyms | DIF, TNFA, TNFSF2, TNF-alpha |
| Source | Escherichia coli |
| Molecular Weight | Approximately 16 kDa, a single non-glycosylated polypeptide chain containing 151 amino acids. |
| Purity | >95% by SDS-PAGE and HPLC analyses. |
| Biological Activity | Fully biologically active. Specific activity ≥ 1.0 × 10^8 units/mg, as determined by murine L929 cell cytolysis in the presence of Actinomycin D. |
| Physical Appearance | White lyophilized powder. |
| Formulation | Lyophilized from a 0.2μm filtered concentrated (1mg/ml) solution in PBS, pH 7.0. |
| Endotoxin | < 1EU/μg of growth factor as determined by LAL method. |
| Reconstitution | Reconstitute in sterile distilled water containing 0.1% BSA to a concentration of 0.1-1.0 mg/mL. |